Stempoint Capital’s Roivant Sciences ROIV Stock Holding History

Stempoint Capital’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12.3M	Sell	348,408 -37,392	-10%	-$1.1M	2.12%	16
2026 Q1	$10.7M	Sell	385,800 -580,898	-60%	-$14.9M	2.05%	13
2025 Q4	$21M	Sell	966,698 -3,230,489	-77%	-$63.7M	3.6%	7
2025 Q3	$63.5M	Buy	4,197,187 +3,595,406	+597%	+$44.5M	12.72%	1
2025 Q2	$6.78M	Sell	601,781 -1,977,079	-77%	-$21.4M	2.18%	17
2025 Q1	$26M	Sell	2,578,860 -133,918	-5%	-$1.45M	8.29%	1
2024 Q4	$32.1M	Sell	2,712,778 -57,041	-2%	-$674K	8.01%	2
2024 Q3	$32M	Buy	2,769,819 +57,078	+2%	+$650K	9.57%	2
2024 Q2	$28.7M	Sell	2,712,741 -841,103	-24%	-$9.22M	8.43%	2
2024 Q1	$37.5M	Buy	3,553,844 +1,384,728	+64%	+$14.9M	9.9%	1
2023 Q4	$24.4M	Buy	+2,169,116	New	+$21.1M	6.5%	1

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Stempoint Capital's ROIV Position: Q2 2026 in Review

Stempoint Capital reduced its Roivant Sciences (ROIV) stake by 9.7% in Q2 2026, selling an estimated $1.1M and leaving 348,408 shares worth $12.3M. The position accounts for 2.12% of the portfolio, ranked #16.

Stempoint Capital first reported a position in ROIV in Q4 2023 and has held it in 11 quarters since. The position peaked at $63.5M in Q3 2025. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Stempoint Capital held 348,408 shares of Roivant Sciences worth $12.3M as of Q2 2026.
Stempoint Capital sold 37,392 Roivant Sciences shares in Q2 2026, an estimated $1.1M.
Roivant Sciences made up 2.12% of Stempoint Capital's portfolio in Q2 2026, its #16 holding.
Stempoint Capital first reported a position in Roivant Sciences in Q4 2023 and has held it in 11 quarters since.
Stempoint Capital's Roivant Sciences position peaked at $63.5M in Q3 2025.
498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.